These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 27411517)

  • 21. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma.
    Slik K; Turkki R; Carpén O; Kurki S; Korkeila E; Sundström J; Pellinen T
    Am J Surg Pathol; 2019 Nov; 43(11):1473-1482. PubMed ID: 31490234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF mutations and the association of V600E with CD133 and CDX2 expression in a Pakistani colorectal carcinoma cohort.
    Hassan S; Mirza T; Khatoon A; Bukhari U; Shaikh F; Karim A
    BMC Cancer; 2024 Sep; 24(1):1162. PubMed ID: 39300378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer.
    Kim JH; Cho NY; Bae JM; Kim KJ; Rhee YY; Lee HS; Kang GH
    Int J Clin Exp Pathol; 2015; 8(2):1920-8. PubMed ID: 25973084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JARID1B promotes colorectal cancer proliferation and Wnt/β-catenin signaling via decreasing CDX2 level.
    Huang D; Xiao F; Hao H; Hua F; Luo Z; Huang Z; Li Q; Chen S; Cheng X; Zhang X; Fang W; Hu X; Liu F
    Cell Commun Signal; 2020 Oct; 18(1):169. PubMed ID: 33109187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
    Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
    Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer.
    Renaud F; Vincent A; Mariette C; Crépin M; Stechly L; Truant S; Copin MC; Porchet N; Leteurtre E; Van Seuningen I; Buisine MP
    Int J Cancer; 2015 Jun; 136(12):2811-21. PubMed ID: 25403854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
    Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
    Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of Hes1 expression is associated with poor prognosis in colorectal adenocarcinoma.
    Ahadi M; Andrici J; Sioson L; Sheen A; Clarkson A; Gill AJ
    Hum Pathol; 2016 Nov; 57():91-97. PubMed ID: 27476040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CDX2 downregulation is associated with poor differentiation and MMR deficiency in colon cancer.
    Olsen J; Eiholm S; Kirkeby LT; Espersen ML; Jess P; Gögenür I; Olsen J; Troelsen JT
    Exp Mol Pathol; 2016 Feb; 100(1):59-66. PubMed ID: 26551082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. OVOL2, an Inhibitor of WNT Signaling, Reduces Invasive Activities of Human and Mouse Cancer Cells and Is Down-regulated in Human Colorectal Tumors.
    Ye GD; Sun GB; Jiao P; Chen C; Liu QF; Huang XL; Zhang R; Cai WY; Li SN; Wu JF; Liu YJ; Wu RS; Xie YY; Chan EC; Liou YC; Li BA
    Gastroenterology; 2016 Mar; 150(3):659-671.e16. PubMed ID: 26619963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancer.
    Xu W; Zhu Y; Shen W; Ding W; Wu T; Guo Y; Chen X; Zhou M; Chen Y; Cui L; Du P
    J Int Med Res; 2019 May; 47(5):1829-1842. PubMed ID: 30616445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxia-inducible factor-1alpha modulates the down-regulation of the homeodomain protein CDX2 in colorectal cancer.
    Zheng J; Sun X; Wang W; Lu S
    Oncol Rep; 2010 Jul; 24(1):97-104. PubMed ID: 20514449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low expression of chloride channel accessory 1 predicts a poor prognosis in colorectal cancer.
    Yang B; Cao L; Liu J; Xu Y; Milne G; Chan W; Heys SD; McCaig CD; Pu J
    Cancer; 2015 May; 121(10):1570-80. PubMed ID: 25603912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
    Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
    Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of CDX2 immunoexpression in poorly differentiated clusters of colorectal carcinoma.
    Reggiani Bonetti L; Lionti S; Vitarelli E; Barresi V
    Virchows Arch; 2017 Dec; 471(6):731-741. PubMed ID: 28819729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
    Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
    Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer.
    Chen KH; Lin YL; Liau JY; Tsai JH; Tseng LH; Lin LI; Liang JT; Lin BR; Hung JS; Chang YL; Yeh KH; Cheng AL
    Med Oncol; 2016 May; 33(5):39. PubMed ID: 27034263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer.
    Sanchez JA; Krumroy L; Plummer S; Aung P; Merkulova A; Skacel M; DeJulius KL; Manilich E; Church JM; Casey G; Kalady MF
    Br J Surg; 2009 Oct; 96(10):1196-204. PubMed ID: 19787768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of SATB2 and CDX2 expression is associated with DNA mismatch repair protein deficiency and BRAF mutation in colorectal cancer.
    Li J; Zeng Q; Lin J; Huang H; Chen L
    Med Mol Morphol; 2024 Mar; 57(1):1-10. PubMed ID: 37583001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.
    Nakaji Y; Oki E; Nakanishi R; Ando K; Sugiyama M; Nakashima Y; Yamashita N; Saeki H; Oda Y; Maehara Y
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):151-160. PubMed ID: 27672042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.